Mimetas said today that it collaborated with Roche (OTC:RHHBY) to develop an organ-on-a-chip system that is designed to evaluate intestinal permeability in 3D gut tubules following exposure to drug compounds using the 10 panel drug tests.
The results of the collaboration were published in Nature Communications.
Get the full story at our sister site, Drug Delivery Business News.